Literature DB >> 16043953

Pulmonary arteriovenous malformations, hereditary hemorrhagic telangiectasia, and brain abscess.

Mauro Gallitelli1, Edoardo Guastamacchia, Francesco Resta, Ginevra Guanti, Carlo Sabbà.   

Abstract

Hereditary hemorrhagic telangiectasia (HHT) is a systemic angiodysplasia inherited as an autosomal dominant disease. Patients with HHT and pulmonary arteriovenous malformations (PAVMs) are at increased risk for brain abscess (BA), a potentially preventable condition as effective treatment for PAVMs is available. In a center dedicated to HHT, a history of BA was found in 6 out of 128 patients with a definite diagnosis: herewith, their histories are reported focusing on mistakes in the diagnosis and management of the disease. Patients with PAVMs and BA had a higher mean hemoglobin concentration (15.1 g/dl vs. 12.2 g/dl, p < 0.006 by Student's t test) compared to patients with PAVMs alone. Other clinical features (genetics, bacteriology, types of PAVMs, treatments, outcomes) are also discussed. Prompt diagnosis and screening for visceral involvement is pivotal for HHT patients and their relatives.

Entities:  

Mesh:

Year:  2005        PMID: 16043953     DOI: 10.1159/000087150

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  3 in total

1.  Pulmonary arteriovenous fistula in hereditary hemorrhagic telangiectasis.

Authors:  Olaf Franzen; Christian Lund; Stephan Baldus
Journal:  Clin Res Cardiol       Date:  2009-11       Impact factor: 5.460

2.  Prevalence of hereditary hemorrhagic telangiectasia in patients operated for cerebral abscess: a retrospective cohort analysis.

Authors:  L Larsen; C R Marker; A D Kjeldsen; F R Poulsen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-06-03       Impact factor: 3.267

3.  Pulmonary arteriovenous malformation causing sudden death due to spontaneous hemothorax.

Authors:  Takaki Ishikawa; Stefan Pollak; René Pflugradt; Michael Bohnert; Markus Grosse Perdekamp; Annette Thierauf; Hitoshi Maeda
Journal:  Int J Legal Med       Date:  2009-12-29       Impact factor: 2.686

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.